A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Completed · Phase 1

Conditions studied: Nonalcoholic Steatohepatitis (NASH)

In brief

This phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH)

Key facts

Study ID

NCT05117489

Run by

Corcept Therapeutics

People needed

70

Starts

2021-11-23

Expected to finish

2024-01-29

Last updated by the study team

2024-08-19

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have a diagnosis of NASH based on a biopsy obtained within the last year OR Have a diagnosis of presumed NASH based on blood tests and scans

You may not qualify if…

• Have participated in another clinical trial within the last year and received active treatment for NASH
• Have participated in another clinical trial for any other indication within the last 3 months
• Are pregnant or lactating women
• Have a BMI <18 kg/m2
• Have had liver transplantation or plan to have liver transplantation during the study
• Have type 1 diabetes or poorly controlled type 2 diabetes.

Where it is running

• Site 207 — Chandler, Arizona, United States
• Site 209 — Tucson, Arizona, United States
• Site 214 — Panorama City, California, United States
• Site 233 — Santa Ana, California, United States
• Site 211 — Austin, Texas, United States
• Site 213 — Edinburg, Texas, United States
• Site 305 — Houston, Texas, United States
• Site 212 — San Antonio, Texas, United States
• 226 — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.